SKB264 ADC: A first-in-human study of SKB264 in patients with locally advanced unresectable/metastatic solid tumors who are refractory to available standard therapies.

Yongheng Liu, Jingyi Wang, Xi Zhao et al.|Journal of Clinical Oncology|2020

Cited by 21